UDI Basics: Basic UDI-DI and UBB Codes
Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
On the coding side of Turkish device compliance, three verifiable statutory actions fall due, and all of them must be completed before the device is placed on the market. Getting the sequence and the terminology right at this stage prevents the most common cascade of defects: codes that exist but do not match the technical file, the declaration of conformity or the databases in which they are supposed to appear.
- Three coding-side actions stand out: assign the Temel UDI-DI (Basic UDI-DI), enter it into the UDI database together with the basic data elements set out in Part B of Annex VI (Ek VI B), and place the UDI carrier on the label or packaging.
- Paragraph 1 of Madde 29 requires that, before placing non-custom devices on the market, the manufacturer assign a Basic UDI-DI as defined in Part C of Annex VI, in accordance with the rules of the designated issuing entities, and enter it into the UDI database together with the basic data elements of Part B of Annex VI.
- Paragraph 1 of Madde 27 defines the two-part structure of the UDI system: the UDI-DI (device identifier, pointing to the manufacturer and the device) and the UDI-PI (production identifier, pointing to the production unit and, where applicable, the packaging).
- The timetable rests expressly on Madde 111, paragraph 1, point (c), corresponding to paragraph 4 of Madde 27: Class III and implantable devices from 2021-05-26; Class IIa and IIb from 2023-05-26; Class I from 2025-05-26; and reusable devices that are themselves supplied with a UDI carrier, in three tiers taking effect in 2023 / 2025 / 2027.
- UBB belongs to the product coding concepts on the ÜTS side; its generation rules are operative-layer matters governed by the TİTCK guide (practical estimate).
2. Legal basis
Three instruments sit behind the coding obligations examined in this article: the Medical Device Regulation itself, the amendment regulation that adjusted the transitional timetable, and the parallel IVD regulation with its own coding provisions. The table records each one with its official reference and the specific articles on which the analysis draws.
| Name of regulation | Original Turkish title | Reference / number | Publication date | Provision |
| Medical Device Regulation | Tıbbi Cihaz Yönetmeliği | Resmî Gazete Sayı 31499 (1. Mükerrer) | 2021-06-02 | Madde 27, Madde 29, Madde 111 paragraph 1 point (c), Parts B / C of Ek VI |
| Amendment Regulation to the Medical Device Regulation (third) | Tıbbi Cihaz Yönetmeliğinde Değişiklik Yapılmasına Dair Yönetmelik | Resmî Gazete Sayı 32635 | 2024-08-17 | Madde 111 paragraph 1 points (a), (c) |
| Regulation on In Vitro Diagnostic Medical Devices | İn Vitro Tanı Amaçlı Tıbbi Cihaz Yönetmeliği | Resmî Gazete Sayı 31499 (1. Mükerrer) | 2021-06-02 | Madde 25, Madde 27, Madde 108 |
3. Expert insights
Insight one: the Basic UDI-DI and the UDI-DI are two levels of coding with distinct functions. The Basic UDI-DI points to a group of devices of the same model family and serves as the linking key across documentation, certificates and databases; the UDI-DI points to the specific device instance at a given packaging level. Confusing the two causes the numbers in the technical documentation, the declaration of conformity and the databases to stop corresponding with one another. Reviewers on both the notified body side and the authority side follow these keys across the file, so a single level error propagates through every document that cites the code.
Insight two: the coding of system procedure packs is independent. Under paragraph 2 of Madde 29, non-custom systems or procedure packs must, before being placed on the market, be assigned their own Basic UDI-DI and entered into the UDI database. Combination businesses must therefore open a separate line for the pack itself in the coding ledger. A pack assembled from components that each carry correct codes is still incomplete from the coding standpoint until its own identifier exists and its own database entry has been made.
Insight three: the IVD timetable runs longer. Under the IVD Regulation, Class D falls due from 2023-05-26, Classes B and C from 2025-05-26, and Class A from 2027-05-26. Set against the MD side, a symmetry emerges: the lowest-risk tiers at both ends — Class I on the MD side and Class A on the IVD side — fall on the 2025 and 2027 nodes respectively, but Class A arrives 2 years later than Class I. Businesses covering both regulations therefore face staggered coding deadlines that must be tracked on separate calendars.
4. Practical recommendations
- Build a three-tier coding ledger: Basic UDI-DI (device group) → UDI-DI (packaging level) → UDI-PI (batch / serial number).
- Open a separate coding line for every system or procedure pack, and mark the position of the pack-level UDI carrier in the label artwork.
- Check go-live dates class by class against Madde 111 paragraph 1 point (c), and list any items past their due date as corrective actions.
5. Verification checklist
- □ A Temel UDI-DI has been assigned for each device group in accordance with the rules of the designated issuing entities.
- □ The basic data elements of Part B of Ek VI have been entered into the UDI database together with the Temel UDI-DI.
- □ The UDI carrier has been placed on the label or packaging (Madde 27).
- □ A separate Temel UDI-DI has been assigned for each system or procedure pack (Madde 29, paragraph 2).
- □ Whether the product line has passed its due date has been checked against the 2021 / 2023 / 2025 / 2027 nodes.
Regulatory information verified to 29 October 2026. The provisions and dates listed in this article were checked against the current text on the Turkish legislative information system (MevzuatNo 38657 and 38658); operative-layer numbering rules such as UBB, for which no official original text was obtained, are handled as a practical estimate.
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Turkish market. Our team prepares CE/UTS-compliant documentation, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us